Catalyst Wire Dossier Catalyst Wire Dossier

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII

EGFRvIII-targeted CAR T cells · National Cancer Institute (NCI)
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CAR T Cell Receptor Immunotherapy Targeting EGFRvIII, covering 2019-08-21 to 2019-08-21. Get the full timeline:

Most recent: Clinical Trial Update: CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII [Phase 1, Phase 2]

See pricing